New Math on Drug Cost-Effectiveness.

The author discusses the rising costs of drugs and existing treatments amidst biomedical improvements, referencing the article "Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma" by R.J. Motzer and colleagues which appeared on page 1803 within the issue. Topics mentioned include the problem Medicare beneficiaries face when it comes to cancer care, the lack of upper limit on coinsurance, and cost-effectiveness analysis as a tool for identifying the value of different treatments.